Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: a Retrospective Cohort Study

BACKGROUND: Immune checkpoint inhibitors (ICIs) are approved in relapsed classic Hodgkin lymphoma (cHL). The safety and effectiveness of allogeneic blood or marrow transplantation (alloBMT) in ICI pretreated cHL patients remain unclear. The aim of this study is to assess outcomes of cHL patients rec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biol Blood Marrow Transplant
Autors principals: Paul, Suman, Zahurak, Marianna, Luznik, Leo, Ambinder, Richard F., Fuchs, Ephraim J., Bolaños-Meade, Javier, Wagner-Johnston, Nina, Swinnen, Lode J., Schoch, Laura, Varadhan, Ravi, Jones, Richard J., Gladstone, Douglas E.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7486273/
https://ncbi.nlm.nih.gov/pubmed/32592857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2020.06.012
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars